Dr. Apar K. Ganti
Claim this profileUniversity of Nebraska Medical Center
Area of expertise
Lung Cancer
Apar K. Ganti has run 6 trials for Lung Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
Apar K. Ganti has run 3 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
University Of Nebraska Medical Center
Nebraska Medicine-Village Pointe
Clinical Trials Apar K. Ganti is currently running
TAB004 + Toripalimab
for Solid Cancers
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004 monotherapy and in combination with toripalimab; and 3) determine the immunogenicity of TAB004 monotherapy and in combination with toripalimab and to determine the immunogenicity of toripalimab when administered with TAB004. The exploratory objectives are to: 1) evaluate pharmacodynamic effects of TAB004 on its target receptor BTLA, as well as effects on the immune system; 2) evaluate biomarkers that may correlate with activity of TAB004 as monotherapy and in combination with toripalimab; 3) evaluate the utility of BTLA ligand, herpesvirus-entry mediator (HVEM), and additional exploratory biomarkers that could aid in selection of appropriate subjects for TAB004 monotherapy and in combination with toripalimab.
Recruiting
1 award
Phase 1
10 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
More about Apar K. Ganti
Clinical Trial Related
10 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Apar K. Ganti has experience with
- Pembrolizumab
- Carboplatin
- Crizotinib
- Capecitabine
- Docetaxel
- Cisplatin
Breakdown of trials Apar K. Ganti has run
Lung Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Anaplastic Large Cell Lymphoma
ALK Gene Rearrangement
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Apar K. Ganti specialize in?
Apar K. Ganti focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage I.
Is Apar K. Ganti currently recruiting for clinical trials?
Yes, Apar K. Ganti is currently recruiting for 3 clinical trials in Omaha Nebraska. If you're interested in participating, you should apply.
Are there any treatments that Apar K. Ganti has studied deeply?
Yes, Apar K. Ganti has studied treatments such as Pembrolizumab, Carboplatin, Crizotinib.
What is the best way to schedule an appointment with Apar K. Ganti?
Apply for one of the trials that Apar K. Ganti is conducting.
What is the office address of Apar K. Ganti?
The office of Apar K. Ganti is located at: University of Nebraska Medical Center, Omaha, Nebraska 68198 United States. This is the address for their practice at the University of Nebraska Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.